RARE - Ultragenyx Pharmaceutical Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Currency in USD

Valuation Measures

Market Cap (intraday) 53.57B
Enterprise Value 32.88B
Trailing P/E N/A
Forward P/E 1-12.57
PEG Ratio (5 yr expected) 1-0.53
Price/Sales (ttm)60.50
Price/Book (mrq)4.01
Enterprise Value/Revenue 348.85
Enterprise Value/EBITDA 6-8.04

Trading Information

Stock Price History

Beta (3Y Monthly) 2.97
52-Week Change 3-23.44%
S&P500 52-Week Change 36.70%
52 Week High 390.98
52 Week Low 337.44
50-Day Moving Average 360.01
200-Day Moving Average 360.40

Share Statistics

Avg Vol (3 month) 3426.05k
Avg Vol (10 day) 3370.57k
Shares Outstanding 5N/A
Float 54.11M
% Held by Insiders 15.92%
% Held by Institutions 192.97%
Shares Short (Jun 28, 2019) 45.47M
Short Ratio (Jun 28, 2019) 413.41
Short % of Float (Jun 28, 2019) 412.96%
Short % of Shares Outstanding (Jun 28, 2019) 49.52%
Shares Short (prior month May 31, 2019) 45.01M

Dividends & Splits

Forward Annual Dividend Rate 4N/A
Forward Annual Dividend Yield 4N/A
Trailing Annual Dividend Rate 3N/A
Trailing Annual Dividend Yield 3N/A
5 Year Average Dividend Yield 4N/A
Payout Ratio 40.00%
Dividend Date 3N/A
Ex-Dividend Date 4N/A
Last Split Factor (new per old) 23/1
Last Split Date 3Jan 17, 2014

Financial Highlights

Fiscal Year

Fiscal Year Ends Dec 31, 2018
Most Recent Quarter (mrq)Mar 31, 2019


Profit Margin 0.00%
Operating Margin (ttm)-634.17%

Management Effectiveness

Return on Assets (ttm)-25.62%
Return on Equity (ttm)-40.32%

Income Statement

Revenue (ttm)58.99M
Revenue Per Share (ttm)1.16
Quarterly Revenue Growth (yoy)70.20%
Gross Profit (ttm)-243.65M
EBITDA -358.6M
Net Income Avi to Common (ttm)-324.62M
Diluted EPS (ttm)-6.37
Quarterly Earnings Growth (yoy)N/A

Balance Sheet

Total Cash (mrq)715.32M
Total Cash Per Share (mrq)12.45
Total Debt (mrq)28.24M
Total Debt/Equity (mrq)3.18
Current Ratio (mrq)11.77
Book Value Per Share (mrq)15.47

Cash Flow Statement

Operating Cash Flow (ttm)-296.86M
Levered Free Cash Flow (ttm)-170.74M